-
-
-
-
-
-
-
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
-
-
-
-
-
-
-
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
-
-
-
-
-
-
-
Astellas Completes Acquisition of Propella Therapeutics
-
-
-
-
-
-
-
Astellas Transfers MYCAMINE® Product Worldwide
-
-
-
-
-
-
-
U.S. FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARδ Modulator being Developed for the Treatment of Primary Mitochondrial Myopathies
-
-
-
-
-
-
-
Astellas Acquires Potenza Therapeutics
-
-
-
-
-
-
-
Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology
-
1,155,357 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

